Skip to content
10-Q

Quarterly Report

Akero Therapeutics, Inc.

0000950170-25-068563

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 79.72M sh
Shares Diluted Q1 2025 · Mar 31, 2025 78.66M sh
Shares Diluted Q1 2025 · Mar 31, 2024 59.31M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$67.66M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$35.14M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $185.92M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $340.24M
Stockholders Equity Q1 2025 · Mar 31, 2025 $1.08B
Stockholders Equity Q1 2025 · Dec 31, 2024 $750.11M
Stockholders Equity Q1 2025 · Mar 31, 2024 $846.25M
Stockholders Equity Q1 2025 · Dec 31, 2023 $535.31M
Current Liabilities Q1 2025 · Mar 31, 2025 $42.44M
Current Liabilities Q1 2025 · Dec 31, 2024 $39.75M
Total Liabilities Q1 2025 · Mar 31, 2025 $72M
Total Liabilities Q1 2025 · Dec 31, 2024 $75.77M
Current Assets Q1 2025 · Mar 31, 2025 $713.15M
Current Assets Q1 2025 · Dec 31, 2024 $770.38M
Total Assets Q1 2025 · Mar 31, 2025 $1.16B
Total Assets Q1 2025 · Dec 31, 2024 $825.89M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.90
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.90
Eps Basic Q1 2025 · Mar 31, 2025 −$0.90
Eps Basic Q1 2025 · Mar 31, 2024 −$0.90
Sga Expense Q1 2025 · Mar 31, 2025 $11.32M
Sga Expense Q1 2025 · Mar 31, 2024 $9.3M
Rd Expense Q1 2025 · Mar 31, 2025 $69.57M
Rd Expense Q1 2025 · Mar 31, 2024 $50.65M
Net Income Q1 2025 · Mar 31, 2025 −$70.73M
Net Income Q1 2025 · Dec 31, 2024 −$252.06M
Net Income Q1 2025 · Mar 31, 2024 −$53.34M
Net Income Q1 2025 · Dec 31, 2023 −$151.76M
Operating Income Q1 2025 · Mar 31, 2025 −$80.88M
Operating Income Q1 2025 · Mar 31, 2024 −$59.95M